Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Broadwood Partners Is Bullish on BioTime, Inc. (BTX)

Broadwood Capital, a fund managed by Neal C. Bradsher has increased its stake in BioTime, Inc. (NYSEMKT:BTX). According to a filing with the SEC, Broadwood currently holds around 9.52 million shares, up from some 9.02 million revealed in the fund’s latest 13F. The stake is activist by nature and amasses 14.1% of the company’s common stock.


Neal C. Bradsher managed Broadwood Capital manages $468 million in equity portfolio with major emphasis on Healthcare, Consumer Goods and Services sector. Among the notable holdings, Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) is worthy of mention. Broadwood holds a $191.21 million position, which contains around 3.30 million shares of the company. Apart from this, Broadwood has investments in Staar Surgical Co. (NASDAQ:STAA), the stake amassing 6.40 million shares, worth $86.68 million and Monster Beverage Corp (NASDAQ:MNST) with a $84.08 million stake, which involves 1.61 million shares.

BioTime Inc. (NASDAQ:BTX) is a bio-tech company focused on regenerative medicine. This field is fast emerging and BioTime is  developing its line of research products like ACTCellerate cell lines, ESpan culture media, HyStem hydrogels, human embryonic stem (hES). BioTime has recently acquired stem cell assets of Geron Corporation (NASDAQ:GERN) for its subsidiary Asterias Biotherapeutics, Inc.

To take the investment further, Asterias has already leased 44,000 square feet of space from a company in California; this will house research, development and manufacturing facility for the cell therapy products. Construction is expected to start as early as the second quarter of 2014 so that the production facility meets current good manufacturing practices of US and European regulators.

Another BioTime Inc. (NASDAQ:BTX)’s subsidiary Cell Cure Neurosciences Ltd. has recently been awarded a $1.7 Million grant from Israel’s Office of the Chief Scientist for developing to help finance the development of OpRegen®, a cell-based therapeutic product in development by Cell Cure for the treatment of age-related macular degeneration, according to a press release by the company.

Disclosure: none

Recommended Reading:

Hedge Fund News: John Paulson, Steven Cohen & David Tepper’s Big Year

Bandera Partners Picks Up Stake in Tandy Leather Factory, Inc. (TLF)

Baker Bros. Advisors Reduces Exposure to MEI Pharma Inc (MEIP) to 3.4%

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!